The SynCorp Saga: Books 1-3

Product Information

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. By qualification Subham holds Master’s degree in Biochemistry from Bangalore University. He had won the Indian Leadership Award for Industrial Development, 2012 from All India Achiever's Foundation, New Delhi. Tenet (2020)". Box Office Mojo. Archived from the original on 3 September 2020 . Retrieved 30 September 2020. Cliantha, by leveraging on the depth of experience provides ethical, value added customer centric services rooted in excellence, thereby enabling clinical development of pharmaceutical, biotech & healthcare companies.

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension. Available from: https://www.cincor.com/news-releases/news-release-details/cincor-pharma-announces-topline-data-phase-2-halo-trial [Last accessed 30 Dec 2022]. Man of Steel (2013)". Box Office Mojo. Archived from the original on 15 December 2014 . Retrieved 14 December 2014. He is also a Senior Advisor to a number of multinational and domestic companies in the healthcare industry. Strong team with International and Indian regulatory experience in writing regulatory documents for USFDA, EMA and DCGI submissions The Prestige (2006)". Box Office Mojo. Archived from the original on 21 June 2009 . Retrieved 3 January 2013.CinCor holds the exclusive, worldwide licence to baxdrostat, which will remain in place following the transaction. Our Goal is to serve our clients and emerge as one of the leaders in life sciences and healthcare sector.

This announcement may include statements that are not statements of historical fact, or “forward-looking statements,” including with respect to AstraZeneca’s proposed acquisition of CinCor. Such forward-looking statements include, but are not limited to, the ability of AstraZeneca and CinCor to complete the transactions contemplated by the acquisition agreement, including the parties’ ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement, statements about the expected timetable for completing the transaction, AstraZeneca’s and CinCor’s beliefs and expectations and statements about the benefits sought to be achieved in AstraZeneca’s proposed acquisition of CinCor, the potential effects of the acquisition on both AstraZeneca and CinCor, the possibility of any termination of the acquisition agreement, as well as the expected benefits and success of baxdrostat and any combination product. These statements are based upon the current beliefs and expectations of AstraZeneca’s and CinCor’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable or at all or that baxdrostat or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. If underlying assumptions prove inaccurate or risks or uncertainties materialise, actual results may differ materially from those set forth in the forward-looking statements. The Dark Knight Rises (2012)". Box Office Mojo. Archived from the original on 5 April 2017 . Retrieved 3 January 2013. Centers for Disease Control and Prevention (CDC) [Internet]. A snapshot: Diabetes in the United States. Available from: https://www.cdc.gov/diabetes/library/socialmedia/infographics/diabetes.html [Last accessed 28 Dec 2022]. At Syncorp Health, multiple functions work in tandem to bring new therapies & devices to market, our Clinical function “Syncorp Health” earlier “Syncorp Clincare” works together with customers to build the tailored made solutions for success. And our unique solutions deliver the value across Small to Mid-size to Large customer continuum.Freeman MW, et al. (2022) Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. NEJM, DOI: 10.1056/NEJMoa2213169. Cliantha Research, full-service Clinical Research Organization (CRO), provides comprehensive and integrated offerings in Early Phase (BA-BE & Phase I), Late Phase (II-IV), Respiratory, Tobacco Research, Dermatology, Consumer Research, Research, Lab services, IVRT, Biometrics, Medical Services, Environmental Exposure Chambers (EECs).